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Abstract:
Objective:
To  explore  the  influence  of  early  treatment  response  to  etanercept-methotrexate  therapy  on  sustained  remission  after
tapering/withdrawal  of  etanercept  in  methotrexate/biologic-naïve  patients  with  early  rheumatoid  arthritis  in  the  PRIZE  study
(ClinicalTrials.gov: NCT00913458).
Method:
In the initial 52-week open-label phase, enrolled patients received once-weekly etanercept 50 mg plus methotrexate. Patients who
achieved  DAS28  ≤3.2  at  week  39  and  <2.6  at  week  52  were  randomized  to  etanercept  25  mg plus  methotrexate,  methotrexate
monotherapy, or placebo once weekly for 39 weeks in the double-blind phase. The relationships between responses in the open-label
phase and sustained remission (DAS28 <2.6 at weeks 76 and 91, without glucocorticoid rescue therapy from weeks 52 to 64) in the
double-blind phase were analyzed.
Results:
In the open-label phase, 70% of patients achieved DAS28 remission at week 52. In the double-blind phase, 63%, 40%, and 23% of
patients had sustained DAS28 remission in the reduced-dose combination-therapy, methotrexate-monotherapy, and placebo groups,
respectively. In patients receiving reduced-dose combination therapy, sustained remission was more likely in those who achieved
DAS28 remission  (p  =  0.005)  or  low disease  activity  (p=0.044)  in  a  shorter  time,  and who had a  lower  DAS28 (p  =  0.016)  or
achieved  ACR/EULAR  Boolean  remission  (p  <  0.05)  at  the  end  of  the  open-label  phase.  In  patients  receiving  methotrexate
monotherapy, sustained remission was associated with a lower acute-phase response (C-reactive protein,  p  = 0.007; erythrocyte
sedimentation rate, p = 0.016) at the end of the open-label phase.
Conclusion:
Fast  response  and  suppression  of  inflammation  with  etanercept-methotrexate  therapy  may  predict  successful  etanercept
tapering/withdrawal  in  patients  with  early  rheumatoid  arthritis.
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1. INTRODUCTION
Clinical remission and Low Disease Activity (LDA) are currently well-recognized treatment targets for patients
with Rheumatoid Arthritis (RA), regardless of the level of their disease activity, because control of inflammation has
been  shown  to  reduce  structural  joint  damage,  quality-of-life  impairment,  and  functional  disability  [1  -  3].  The
effectiveness of combination therapy with an anti-Tumor Necrosis Factor (TNF) agent and the conventional Disease-
Modifying Antirheumatic Drug (DMARD) methotrexate in early RA has been demonstrated over decades of clinical
research  [4  -  9].  In  patients  who  achieve  remission,  clinicians  may  consider  biologic  dose  reduction  or  complete
withdrawal due to concerns regarding adverse event risk and cost [10], but such an approach requires an understanding
of the factors that influence remission maintenance after de-escalation of anti-TNF therapy. However, identification of
patients who may be most likely to achieve a sustained response with a maintenance regimen remains a challenge, as
little definitive evidence on predictive markers is available.
During the open-label first phase of the PRIZE (Productivity and Remission in a randomIZed controlled trial of
etanercept vs standard of care in Early rheumatoid arthritis) study, patients with early, active, moderate-to-severe RA
showed  significant  and  rapid  improvement  in  disease  activity  and  function  with  combined  50  mg  etanercept  once
weekly (QW) with methotrexate therapy [11].  In this early RA population,  induction therapy with the combination
regimen  was  associated  with  remission  or  LDA in  most  of  the  treated  patients.  In  the  double-blind  second  phase,
patients  with  qualifying  responses  at  weeks  39  and  52  of  the  open-label  phase  were  randomized  to  receive  either
combination  25  mg etanercept  plus  methotrexate,  methotrexate  monotherapy,  or  placebo QW for  39  weeks.  Better
disease control was maintained by continuing the combination regimen, albeit with a reduced biologic dose, than by
switching to methotrexate monotherapy or placebo. The design and patient populations of the PRIZE study provided the
opportunity to examine factors that may have influenced the maintenance of remission in the double-blind phase after
etanercept was tapered or withdrawn among patients who initially responded to induction therapy with the full-dose
regimen.
2. PATIENTS AND METHODS
The  population  and  methodology  of  the  PRIZE  study  (ClinicalTrials.gov  identifier:  NCT00913458)  have  been
described in detail in a previous publication [11]. In brief, eligible patients had moderate-to-severe RA, symptom onset
within 12 months of enrollment,  and no prior exposure to methotrexate or biologic agents.  In the initial  open-label
phase (Supplemental Fig. S1), patients received subcutaneous (SC) etanercept 50 mg plus oral methotrexate 10 mg (up
to a maximum dose of 25 mg) QW for 52 weeks. Patients who met the criteria for response, defined as Disease Activity
Score for 28-joint counts (DAS28) LDA at week 39 and DAS28 <2.6 (i.e., remission) at week 52 were randomized to
receive SC etanercept 25 mg plus oral methotrexate (i.e., combination therapy), oral methotrexate plus SC placebo (i.e.,
methotrexate monotherapy), or SC and oral placebo (i.e., placebo) during the subsequent 39-week double-blind phase.
At  weeks  12,  24,  and  39  of  the  double-blind  phase,  patients  with  a  DAS28  >3.2  were  withdrawn  from  the  study.
Randomized treatment was discontinued in patients who achieved DAS28 LDA at week 39 of the latter phase, and these
patients were observed through the final 26-week withdrawal phase of the study. Radiographs of the hands, wrists, and
feet were taken at baseline of the open-label phase and the start and end of the double-blind phase; the images were
assessed by a central blinded reader and scored based on the van der Heijde modification of total Sharp score (modified
Total Sharp Score [mTSS]).
In prespecified exploratory and post hoc analyses, patients’ demographic and disease characteristics at baseline and
treatment responses in the open-label phase were evaluated as predictors of sustained remission in the double-blind
phase.  Sustained  remission  was  defined  as  achievement  of  DAS28  <2.6  at  weeks  76  and  91,  without  the  need  for
glucocorticoid rescue therapy from weeks 52 to 64. Baseline demographic and disease characteristics included in these
analyses as predictive variables were age and sex; disease duration; prior use of corticosteroids or nonsteroidal anti-
inflammatory drugs; anti-Cyclic Citrullinated Peptide antibody (aCCP) and Rheumatoid Factor (RF) status; C-Reactive
Protein (CRP) level and erythrocyte sedimentation rate (ESR); tender and swollen joint counts; DAS28; scores on the
Health Assessment Questionnaire (HAQ), Physician and Subject Global Assessments (PGA and SGA), pain Visual
Analog Scale (VAS), and Medical Outcomes Short Form-36 Health Survey; and mTSS. Treatment responses at week
52 of the open-label phase that were included in the analyses as predictive variables were CRP levels and ESR; DAS28
remission  and  LDA;  remission  according  to  American  College  of  Rheumatology/European  League  Against
Rheumatism  (ACR/EULAR)  Boolean  criteria;  DAS28;  scores  on  HAQ,  PGA,  SGA,  pain  VAS,  and  Functional
Assessment  of  Chronic  Illness-fatigue;  and  the  mTSS.
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These  analyses  were  conducted in  the  double-blind modified  Intent-To-Treat  (mITT) population,  defined as  all
patients  who  had  received  ≥1  dose  of  treatment  in  the  double-blind  phase  and  had  ≥1  DAS28  assessment  after
randomization,  using  nonresponder  imputation  (i.e.,  all  patients  who  dropped  out  of  the  study  were  identified  as
nonresponders). Relationships among baseline characteristics, early treatment outcomes, and sustained remission were
analyzed  using  Odds  Ratios  (ORs)  from  univariate  logistic  regression  models,  with  treatment  as  factor;
Mantel–Haenszel chi-square correlation trend test (univariate analyses of quartiles of response); and stepwise logistic
regression.
3. RESULTS
3.1. Patient Disposition
Of the 306 patients enrolled in the PRIZE study, 222 completed the 52-week open-label phase, and 198 achieved a
treatment response with full-dose combination therapy (Supplemental Fig. S1) [11]. Of the responders, 193 entered the
double-blind phase and were randomized to treatment with either reduced-dose combination etanercept-methotrexate
therapy (n = 63), methotrexate monotherapy (n = 65), or placebo (n = 65), and 132 achieved a response after 39 weeks
of double-blind treatment.
3.2. Response in the Open-Label and Double-Blind Phases
In the open-label phase, in which all patients received etanercept 50 mg plus methotrexate, 70%, 61%, 57%, and
51%  of  patients  achieved  remission  according  to  the  DAS28,  Simplified  Disease  Activity  Index  (SDAI),  Clinical
Disease Activity Index (CDAI), and ACR/EULAR Boolean criteria, respectively, at week 52 (Fig. 1A). A total of 78%,
81%, and 81% of patients attained LDA based on DAS28, SDAI, and CDAI, respectively, and 67% attained normal
HAQ-DI. Among patients who met response criteria and were randomized to treatment in the double-blind phase, 63%,
40%, and 23% in the reduced-dose combination therapy, methotrexate monotherapy, and placebo groups, respectively,
achieved  sustained  DAS28  remission  by  the  end  of  the  double-blind  phase  (Fig.  1B;  combination  therapy  vs.
methotrexate,  p<0.01  and  vs.  placebo,  p<0.0001).
Fig.  (1).  (A)  The  proportion  of  patients  receiving  etanercept  50  mg  plus  methotrexate  in  the  open-label  mITT population  who
achieved clinical  and functional  end points  at  the  final  visit  of  the  open-label  phase  (LOCF,  observed cases).  All  comparisons,
p<0.0001  versus  baseline.  (B)  The  proportion  of  patients  randomized  to  reduced-dose  (25  mg)  etanercept  plus  methotrexate
combination therapy, methotrexate monotherapy, or placebo in the double-blind mITT population who achieved sustained remission
in the double-blind period by randomized treatment group (NRI). *p<0.01 combination versus methotrexate monotherapy; †p<0.0001
combination  versus  placebo;  ‡p<0.02  methotrexate  monotherapy  versus  placebo  (mITT).  Observed  cases  =  completers.
ACR/EULAR: American College of Rheumatology/European League Against Rheumatism; CDAI: Clinical Disease Activity Index;
DAS28: Disease Activity Score for 28-joint counts; LDA: Low Disease Activity; LOCF: Last Observation Carried Forward; mITT:
modified Intent-To-Treat; NRI: Nonresponder imputation; SDAI: Simplified Disease Activity Index.
3.3. Predictors of Sustained Response in the Double-blind Phase
None  of  the  baseline  demographic  or  disease  characteristic  predictors  analyzed  was  found  to  predict  sustained
remission with the reduced-dose combination regimen (etanercept 25 mg plus methotrexate) in the double-blind phase
(Fig. 2A). Sustained remission with methotrexate monotherapy was significantly more likely in younger patients (p =
0.028; Fig. 2B), and with placebo, in those who were negative for aCCP (p = 0.002) or RF (p = 0.007) (Fig. 2C).
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Fig.  (2).  Demographic  and  disease  characteristics  at  baseline  as  predictors  of  sustained  remission  in  patients  who received  (A)
reduced-dose combination therapy, (B) methotrexate monotherapy, and (C) placebo in the double-blind phase (double-blind mITT
population). aCCP: anticyclic citrullinated peptide antibody; CI: confidence interval; CRP: C-Reactive Protein; DAS28: Disease
Activity Score for 28-joint counts; ESR: Erythrocyte Sedimentation Rate; HAQ: Health Assessment Questionnaire; mITT: modified
intent-to-treat;  mTSS: modified Total  Sharp Score;  NSAID: Nonsteroidal  Anti-Inflammatory Drug;  PCS: Physician Component
Summary; PGA: Physician Global Assessment; RF: Rheumatoid Factor; SF-36: Medical Outcomes Short Form-36 Health Survey;
SGA: Subject Global Assessment ; SJC: Swollen Joint Count; TJC: Tender Joint Count; VAS: Visual Analog Scale.
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Sustained remission with the reduced-dose combination therapy was significantly more likely in patients who had
achieved DAS28 remission (p=0.005) or LDA (p=0.044) in a shorter time with induction therapy and who had a lower
DAS28 (p=0.016; Fig. 3A) at the end of the open-label phase. With methotrexate monotherapy, sustained remission was
associated with lower CRP (p=0.007) or ESR (p=0.016) levels at week 52 (Fig. 3B). No early response predictors of
sustained remission were found with placebo (Fig. 3C).
Fig. (3). Treatment responses at week 52 as predictors of sustained remission in patients who received (A) reduced-dose combination
therapy, (B) methotrexate monotherapy, and (C) placebo in the double-blind phase (double-blind mITT population). ACR/EULAR:
American College of Rheumatology/European League Against Rheumatism; CI: Confidence Interval; CRP: C-Reactive Protein;
DAS28:  Disease  Activity  Score  for  28-joint  counts;  ESR:  Erythrocyte  Sedimentation  Rate;  FACIT:  Functional  Assessment  of
Chronic Illness; HAQ: Health Assessment Questionnaire; LDA: Low Disease Activity; mITT: modified Intent-To-Treat; mTSS:
modified Total Sharp Score; PGA: Physician Global Assessment; SGA: Subject Global Assessment; VAS: Visual Analog Scale.
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In post hoc univariate analyses, a significantly higher proportion of patients who achieved sustained remission with
reduced-dose combination therapy had achieved first DAS28 remission (p<0.01) or LDA (p<0.05) in a shorter time
with induction therapy and had a lower DAS28 at week 52 (p<0.05; Table 1). Sustained remission with the reduced-
dose regimen was also significantly more likely among patients who achieved ACR/EULAR Boolean remission at week
52 with induction therapy compared with those who did not (71% vs. 44%; p<0.05). Patients who achieved sustained
remission with methotrexate monotherapy were more likely to have been younger (p<0.05) and to have had lower CRP
levels at baseline (p <0.01; Table 1). In the methotrexate monotherapy group, sustained remission was achieved by 49%
of patients who had DAS28 LDA from weeks 13 to 52 of the open-label phase compared with 23% of those who did
not  (p  <0.05).  Sustained  remission  with  placebo  was  reported  in  higher  proportions  of  patients  who  had  been
seronegative at baseline for aCCP (seronegative vs. seropositive: 48% vs. 11%; p≤0.01) and for RF (41% vs. 11%; p
<0.01) antibodies.
Table 1. Baseline and treatment response factors predictive of sustained remission in the double-blind phase in the active
treatment groups.
Predictor Quartiles of Response, n/N (%) p-value*
Reduced-Dose Combination Therapy
First DAS28 remission, day 13–57 58–179 180–273 ≥274
    n/N (%) 12/15 (80) 16/20 (80) 8/16 (50) 4/12 (33) <0.01
First DAS28 LDA, day 1–29 30–57 58–183 ≥184
    n/N (%) 12/14 (86) 12/20 (60) 10/15 (67) 6/14 (43) <0.05
Mean DAS28, week 52 ≤1.55 >1.55−1.91 >1.91−2.16 >2.16
    n/N (%) 14/16 (88) 11/16 (69) 7/15 (47) 8/16 (50) <0.05
Methotrexate Monotherapy
Age, BL, years 19–39 40–48 49–60 ≥61
    n/N (%) 11/15 (73) 8/22 (36) 2/15 (13) 5/13 (38) <0.05
CRP level, week 52, mg/L 0–0.50 >0.50–1.09 >1.09–2.91 >2.91
    n/N (%) 9/16 (56) 8/14 (57) 6/18 (33) 2/16 (13) <0.01
* Mantel–Haenszel chi-square correlation (trend) test (univariate).
BL: baseline; CRP: C-Reactive Protein; DAS28: Disease Activity Score for 28-joint counts; LDA: Low Disease Activity.
When the relationship between baseline demographic and disease characteristics and sustained remission in the
double-blind phase was analyzed using stepwise logistic regression, sustained remission in the placebo group was more
likely among patients who had been seronegative versus seropositive for aCCP antibody at baseline (OR, 7.799; 95%
confidence interval [CI] 2.171–28.015). In analyses of early treatment response and sustained remission, patients who
achieved DAS28 remission in  a  shorter  time with  induction therapy were  more  likely  to  maintain  remission in  the
reduced-dose combination therapy group (OR, 1.008; 95% CI 1.003-1.014); patients who had lower ESR levels after
induction therapy were more likely to have sustained remission with methotrexate monotherapy (OR, 1.171; 95% CI
1.033-1.328).
4. DISCUSSION
Recent EULAR recommendations for the treatment of RA [3] suggest that induction therapy with a biologic plus
conventional DMARD followed by tapering or discontinuation of the biologic and continuation of the conventional
DMARD may be a valuable approach, which is supported by multiple reports in the literature [11 - 16]. However, the
EULAR Committee advised that biologics should be tapered primarily when used in combination with conventional
DMARDs to achieve sustained remission, as their discontinuation frequently results in a recurrence of disease activity
[17, 18]. Although a few predictors of successful biologic tapering in initial responders have been identified [10], such
characteristics have not yet been adequately studied.
In  the  open-label  induction  phase  of  the  PRIZE  study,  patients  who  had  not  previously  been  treated  with
methotrexate or biologic therapy showed significant and rapid improvement in clinical and functional outcomes with
full-dose etanercept-methotrexate combination induction therapy. Among patients who responded to induction therapy,
remission was more effectively maintained with a reduced-dose combination therapy regimen than with a biologic-free
regimen in the double-blind phase. In the latter maintenance phase, early onset of response to induction therapy with the
full-dose regimen was an important predictor of subsequently sustained remission after tapering of etanercept. The key
factors predicting patients’ achievement of sustained remission with reduced-dose combination maintenance therapy
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were early first remission, early first LDA, low DAS28, and ACR/EULAR Boolean remission with induction therapy.
Predictors of biologic-free sustained remission after etanercept withdrawal, i.e., in the methotrexate monotherapy and
placebo groups, included younger age and aCCP– / RF– status at baseline, and lower acute-phase response and early
persistent response after open-label treatment with the full-dose combination regimen.
Our  findings  that  short-term  treatment  response  is  predictive  of  future  outcomes  are  consistent  with  those  of
multiple  other  studies  [19  -  26],  although  the  aforementioned  analyses  of  predictors  of  biologic-free  remission  are
unique. In a post hoc analysis of the PREMIER study, patients with early, aggressive RA who had an early, more robust
response to methotrexate monotherapy demonstrated more favorable clinical, functional, and radiographic long-term
outcomes than those with a delayed, less robust response [26]. Patients with an early or higher magnitude response to
methotrexate/anti-TNF combination  therapy  showed less  difference  in  long-term outcomes,  although  some upward
trends were observed. In the TEAR trial, conducted in methotrexate-refractory patients with moderate-to-severe early
RA, clinical response achieved within 3 months of initiating or escalating conventional DMARD/biologic therapy was
shown to be a reliable predictor of LDA at 1 year [24].
The results of the PRIZE study, which support an intensive treatment strategy targeting achievement of DAS28 or
ACR/EULAR Boolean remission in patients with early RA prior to biologic tapering or withdrawal, also build on those
of other randomized, controlled, double-blind clinical trials that have demonstrated the benefits of early intervention [6,
27,  28].  In  the  Combination  of  Methotrexate  and  Etanercept  in  Early  Rheumatoid  Arthritis  (COMET)  trial,  a
significantly greater proportion of patients in the etanercept-methotrexate combination therapy group achieved DAS28
remission after 52 weeks of treatment compared with patients in the methotrexate monotherapy group (50% vs. 28%; p
< 0.0001) [28]. Importantly, remission rates observed in the COMET population (mean disease duration, 9.0 months)
were  ~10%  higher  than  those  reported  in  the  TEMPO  study  with  combination  and  methotrexate  therapies  in  a
population with more established RA (mean disease duration, 6.8 years) [29]. In addition, post hoc analysis of COMET
trial data revealed that treatment with etanercept plus methotrexate provided qualitatively better clinical outcomes in
very early RA (disease duration ≤ 4 months) than in early RA (> 4 months to 2 years): DAS28 remission was achieved
in  70% versus  48% (p  <0.05)  of  patients  in  the  very  early  versus  early  RA  groups,  respectively  [30].  These  high
remission rates were not observed with methotrexate monotherapy (35% vs. 32%, respectively; p>0.70).
Limitations of the PRIZE study have been previously presented [11]. This study was designed to examine whether
the  efficacy  of  full-dose  etanercept-methotrexate  induction  therapy  would  be  maintained  after  the  reduction  or
withdrawal  of  the  biologic  in  patients  with  early,  moderate-to-severe  RA  who  previously  responded  to  induction
therapy. Because no patients received full-dose combination therapy in the double-blind phase, we could not directly
compare the efficacy of dose tapering or discontinuation with that of continuing full-dose therapy in this population.
Many  of  the  analyses  in  the  current  report  were  based  on  post  hoc  models,  with  no  multiple  comparison  control.
Moreover,  our  findings  may  not  be  reproducible  and  should  not  be  considered  generalizable  or  predictive.  The
predictors reported in the current  paper were derived from patients  who had not  received previous methotrexate or
biologic therapy.
CONCLUSION
In patients with RA, identification of baseline characteristics and early clinical outcomes that predict future response
to maintenance therapy with conventional DMARD and/or biologic therapy may improve clinicians’ decision-making
when managing this  chronic,  potentially  disabling  disease.  A patient’s  demographic  and disease  features  and early
response may help inform the clinician’s choice to either stay the course with the originally selected therapeutic agent
or regimen; modify the original approach via addition, subtraction, or dose adjustment; or switch to an entirely different
agent or regimen, in the pursuit of remission or an LDA state. Our results and those reported previously are clinically
relevant, as they may allow more timely therapeutic adjustments and better long-term outcomes. They suggest that an
early aggressive treat-to-target approach may be best if subsequent de-escalation of biologic therapy is desired. In the
practice  setting,  clinicians  may  consider  patients  who  achieve  a  rapid  clinical  response,  ACR/EULAR  Boolean
remission, and/or more complete suppression of inflammatory markers with full-dose etanercept-methotrexate therapy
as the most appropriate candidates for a trial of biologic dose reduction or withdrawal. However, additional research is
needed to detect not only single predictors of treatment response, but also sets of multiple predictors that will improve
management of early and established RA of patients in clinical practice.
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